Limitations of bacterial culture, viral PCR, and tulathromycin susceptibility from upper respiratory tract samples in predicting clinical outcome of tulathromycin control or treatment of bovine respiratory disease in high-risk feeder heifers
A cross-sectional prospective cohort study including 1026 heifers administered tulathromycin due to high risk of clinical signs of bovine respiratory disease (BRD), measured poor association between BRD clinical outcomes and results of bacterial culture and tulathromycin susceptibility from BRD isol...
Gespeichert in:
| Veröffentlicht in: | PloS one 2022-02, Vol.17 (2), p.e0247213-e0247213 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | e0247213 |
|---|---|
| container_issue | 2 |
| container_start_page | e0247213 |
| container_title | PloS one |
| container_volume | 17 |
| creator | Sarchet, Jeffrey J Pollreisz, John P Bechtol, David T Blanding, Mitchell R Saltman, Roger L Taube, Patrick C |
| description | A cross-sectional prospective cohort study including 1026 heifers administered tulathromycin due to high risk of clinical signs of bovine respiratory disease (BRD), measured poor association between BRD clinical outcomes and results of bacterial culture and tulathromycin susceptibility from BRD isolates of deep nasopharyngeal swabs (DNS) and adequate association with viral polymerase chain reaction (PCR) results from nasal swabs. Isolation rates from DNS collected on day-0 and at 1st BRD-treatment respectively were: Mannheimia haemolytica (10.9% & 34.1%); Pasteurella multocida (10.4% & 7.4%); Mycoplasma bovis (1.0% & 36.6%); and Histophilus somni (0.7% & 6.3%). Prevalence of BRD viral nucleic acid on nasal swabs collected exclusively at 1st BRD-treatment were: bovine parainfluenza virus type-3 (bPIV-3) 34.1%; bovine viral diarrhea virus (BVDV) 26.3%; bovine herpes virus type-1 (BHV-1) 10.8%; and bovine respiratory syncytial virus (BRSV) 54.1%. Increased relative risk, at 95% confidence intervals, of 1st BRD-treatment failure was associated with positive viral PCR results: BVDV 1.39 (1.17-1.66), bPIV-3 1.26 (1.06-1.51), BHV-1 1.52 (1.25-1.83), and BRSV 1.35 (1.11-1.63) from nasal swabs collected at 1st BRD-treatment and culture of M. haemolytica 1.23 (1.00-1.51) from DNS collected at day-0. However, in this population of high-risk feeder heifers, the predictive values of susceptible and resistant isolates had inadequate association with BRD clinical outcome. These results indicate, that using tulathromycin susceptibility testing of isolates of M. haemolytica or P. multocida from DNS collected on arrival or at 1st BRD-treatment to evaluate tulathromycin clinical efficacy, is unreliable. |
| doi_str_mv | 10.1371/journal.pone.0247213 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_plos_</sourceid><recordid>TN_cdi_plos_journals_2627454694</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A692894629</galeid><doaj_id>oai_doaj_org_article_3eb875cb53f64d6684940339238599e0</doaj_id><sourcerecordid>A692894629</sourcerecordid><originalsourceid>FETCH-LOGICAL-c692t-e3f60089c417cf0a8646319623b34d025c15606fd99ecd48c91ae92f850c1cb3</originalsourceid><addsrcrecordid>eNqNU19r1TAUL6K4Of0GogFBFHavaZPmNi_CGP4ZDCZz-BrS9PQ2M01qkl68H9tvYHp3N1bZg_Qhzcnvz8k5OVn2MsfLnKzyD9du9Faa5eAsLHFBV0VOHmWHOSfFghWYPL73f5A9C-Ea45JUjD3NDkiZU1Jiepj9Ode9jjJqZwNyLaqliuC1NEiNJo4ejtFG-7T9dnp5jKRtUByNjJ13_VZpi8IYFAxR19rouEVtiqNxGMAjD2FIzOj8FkWfZFGQ_WAgoEQbPDRaRW3XSBlttUoObozK9TBlMfdQzkbvEsAnIZCxBxt3ubqNtjAzanQAGWCy6PS6W3gdfqIWoEkJdaBb8OF59qSVJsCL_XqUXX3-dHX6dXF-8eXs9OR8oRgv4gJIyzCuuKL5SrVYVowyknNWkJrQBhelykuGWdtwDqqhleK5BF60VYlVrmpylL2-kR2MC2LfrCAKVqxoSRmnCXF2g2icvBaD1730W-GkFruA82shfdTKgCBQV6tS1WVKijaMVZRTTAgvSFUmf5y0Pu7dxrqHRqUKpabNROcnVndi7TaiqghmJU8C7_YC3v0aIUTR69RZY6QFN-7yrgrOGJu83vwDffh2e9Rapgto27rpEUyi4iQVuOKUFZPt8gFU-hrodeo7tDrFZ4T3M8L0NuB3XMsxBHH2_fL_sRc_5ti397AdSBO74My4G4w5kN4AlXcheGjvipxjMQ3mbTXENJhiP5iJ9up-g-5It5NI_gLc_Tn6</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2627454694</pqid></control><display><type>article</type><title>Limitations of bacterial culture, viral PCR, and tulathromycin susceptibility from upper respiratory tract samples in predicting clinical outcome of tulathromycin control or treatment of bovine respiratory disease in high-risk feeder heifers</title><source>Public Library of Science (PLoS) Journals Open Access</source><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><source>Free Full-Text Journals in Chemistry</source><creator>Sarchet, Jeffrey J ; Pollreisz, John P ; Bechtol, David T ; Blanding, Mitchell R ; Saltman, Roger L ; Taube, Patrick C</creator><contributor>Clegg, Simon</contributor><creatorcontrib>Sarchet, Jeffrey J ; Pollreisz, John P ; Bechtol, David T ; Blanding, Mitchell R ; Saltman, Roger L ; Taube, Patrick C ; Clegg, Simon</creatorcontrib><description>A cross-sectional prospective cohort study including 1026 heifers administered tulathromycin due to high risk of clinical signs of bovine respiratory disease (BRD), measured poor association between BRD clinical outcomes and results of bacterial culture and tulathromycin susceptibility from BRD isolates of deep nasopharyngeal swabs (DNS) and adequate association with viral polymerase chain reaction (PCR) results from nasal swabs. Isolation rates from DNS collected on day-0 and at 1st BRD-treatment respectively were: Mannheimia haemolytica (10.9% & 34.1%); Pasteurella multocida (10.4% & 7.4%); Mycoplasma bovis (1.0% & 36.6%); and Histophilus somni (0.7% & 6.3%). Prevalence of BRD viral nucleic acid on nasal swabs collected exclusively at 1st BRD-treatment were: bovine parainfluenza virus type-3 (bPIV-3) 34.1%; bovine viral diarrhea virus (BVDV) 26.3%; bovine herpes virus type-1 (BHV-1) 10.8%; and bovine respiratory syncytial virus (BRSV) 54.1%. Increased relative risk, at 95% confidence intervals, of 1st BRD-treatment failure was associated with positive viral PCR results: BVDV 1.39 (1.17-1.66), bPIV-3 1.26 (1.06-1.51), BHV-1 1.52 (1.25-1.83), and BRSV 1.35 (1.11-1.63) from nasal swabs collected at 1st BRD-treatment and culture of M. haemolytica 1.23 (1.00-1.51) from DNS collected at day-0. However, in this population of high-risk feeder heifers, the predictive values of susceptible and resistant isolates had inadequate association with BRD clinical outcome. These results indicate, that using tulathromycin susceptibility testing of isolates of M. haemolytica or P. multocida from DNS collected on arrival or at 1st BRD-treatment to evaluate tulathromycin clinical efficacy, is unreliable.</description><identifier>ISSN: 1932-6203</identifier><identifier>EISSN: 1932-6203</identifier><identifier>DOI: 10.1371/journal.pone.0247213</identifier><identifier>PMID: 35143504</identifier><language>eng</language><publisher>United States: Public Library of Science</publisher><subject>Analysis ; Animals ; Anti-Bacterial Agents - pharmacology ; Anti-Bacterial Agents - therapeutic use ; Antimicrobial agents ; Bacterial infections ; Biology and Life Sciences ; Bovine respiratory disease complex ; Bovine Respiratory Disease Complex - drug therapy ; Bovine Respiratory Disease Complex - microbiology ; Bovine Respiratory Disease Complex - pathology ; Care and treatment ; Cattle ; Cattle Diseases - drug therapy ; Cattle Diseases - microbiology ; Cattle Diseases - pathology ; Clinical outcomes ; Confidence intervals ; Cross-Sectional Studies ; Diarrhea ; Diarrhea Viruses, Bovine Viral - drug effects ; Diarrhea Viruses, Bovine Viral - genetics ; Diarrhea Viruses, Bovine Viral - isolation & purification ; Disaccharides - pharmacology ; Disaccharides - therapeutic use ; DNA, Viral - genetics ; DNA, Viral - metabolism ; Drug dosages ; Health risks ; Health services ; Herpesvirus 1, Bovine - drug effects ; Herpesvirus 1, Bovine - genetics ; Herpesvirus 1, Bovine - isolation & purification ; Heterocyclic Compounds - pharmacology ; Heterocyclic Compounds - therapeutic use ; Infections ; Mannheimia haemolytica - drug effects ; Mannheimia haemolytica - isolation & purification ; Medicine and Health Sciences ; Microbial Sensitivity Tests ; Nasopharynx - microbiology ; Nasopharynx - virology ; Nucleic acids ; Parainfluenza ; Pasteurella multocida - drug effects ; Pasteurella multocida - isolation & purification ; Pathogens ; Polymerase Chain Reaction ; Prospective Studies ; Respiratory diseases ; Respiratory syncytial virus ; Respiratory Syncytial Virus, Bovine - drug effects ; Respiratory Syncytial Virus, Bovine - genetics ; Respiratory Syncytial Virus, Bovine - isolation & purification ; Respiratory tract ; Risk ; Risk Factors ; RNA, Viral - genetics ; RNA, Viral - metabolism ; Treatment Failure ; Veterinary medicine ; Viruses</subject><ispartof>PloS one, 2022-02, Vol.17 (2), p.e0247213-e0247213</ispartof><rights>COPYRIGHT 2022 Public Library of Science</rights><rights>2022 Sarchet et al. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2022 Sarchet et al 2022 Sarchet et al</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c692t-e3f60089c417cf0a8646319623b34d025c15606fd99ecd48c91ae92f850c1cb3</citedby><cites>FETCH-LOGICAL-c692t-e3f60089c417cf0a8646319623b34d025c15606fd99ecd48c91ae92f850c1cb3</cites><orcidid>0000-0002-6325-090X</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8830659/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8830659/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,315,729,782,786,866,887,2106,2932,23875,27933,27934,53800,53802</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35143504$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><contributor>Clegg, Simon</contributor><creatorcontrib>Sarchet, Jeffrey J</creatorcontrib><creatorcontrib>Pollreisz, John P</creatorcontrib><creatorcontrib>Bechtol, David T</creatorcontrib><creatorcontrib>Blanding, Mitchell R</creatorcontrib><creatorcontrib>Saltman, Roger L</creatorcontrib><creatorcontrib>Taube, Patrick C</creatorcontrib><title>Limitations of bacterial culture, viral PCR, and tulathromycin susceptibility from upper respiratory tract samples in predicting clinical outcome of tulathromycin control or treatment of bovine respiratory disease in high-risk feeder heifers</title><title>PloS one</title><addtitle>PLoS One</addtitle><description>A cross-sectional prospective cohort study including 1026 heifers administered tulathromycin due to high risk of clinical signs of bovine respiratory disease (BRD), measured poor association between BRD clinical outcomes and results of bacterial culture and tulathromycin susceptibility from BRD isolates of deep nasopharyngeal swabs (DNS) and adequate association with viral polymerase chain reaction (PCR) results from nasal swabs. Isolation rates from DNS collected on day-0 and at 1st BRD-treatment respectively were: Mannheimia haemolytica (10.9% & 34.1%); Pasteurella multocida (10.4% & 7.4%); Mycoplasma bovis (1.0% & 36.6%); and Histophilus somni (0.7% & 6.3%). Prevalence of BRD viral nucleic acid on nasal swabs collected exclusively at 1st BRD-treatment were: bovine parainfluenza virus type-3 (bPIV-3) 34.1%; bovine viral diarrhea virus (BVDV) 26.3%; bovine herpes virus type-1 (BHV-1) 10.8%; and bovine respiratory syncytial virus (BRSV) 54.1%. Increased relative risk, at 95% confidence intervals, of 1st BRD-treatment failure was associated with positive viral PCR results: BVDV 1.39 (1.17-1.66), bPIV-3 1.26 (1.06-1.51), BHV-1 1.52 (1.25-1.83), and BRSV 1.35 (1.11-1.63) from nasal swabs collected at 1st BRD-treatment and culture of M. haemolytica 1.23 (1.00-1.51) from DNS collected at day-0. However, in this population of high-risk feeder heifers, the predictive values of susceptible and resistant isolates had inadequate association with BRD clinical outcome. These results indicate, that using tulathromycin susceptibility testing of isolates of M. haemolytica or P. multocida from DNS collected on arrival or at 1st BRD-treatment to evaluate tulathromycin clinical efficacy, is unreliable.</description><subject>Analysis</subject><subject>Animals</subject><subject>Anti-Bacterial Agents - pharmacology</subject><subject>Anti-Bacterial Agents - therapeutic use</subject><subject>Antimicrobial agents</subject><subject>Bacterial infections</subject><subject>Biology and Life Sciences</subject><subject>Bovine respiratory disease complex</subject><subject>Bovine Respiratory Disease Complex - drug therapy</subject><subject>Bovine Respiratory Disease Complex - microbiology</subject><subject>Bovine Respiratory Disease Complex - pathology</subject><subject>Care and treatment</subject><subject>Cattle</subject><subject>Cattle Diseases - drug therapy</subject><subject>Cattle Diseases - microbiology</subject><subject>Cattle Diseases - pathology</subject><subject>Clinical outcomes</subject><subject>Confidence intervals</subject><subject>Cross-Sectional Studies</subject><subject>Diarrhea</subject><subject>Diarrhea Viruses, Bovine Viral - drug effects</subject><subject>Diarrhea Viruses, Bovine Viral - genetics</subject><subject>Diarrhea Viruses, Bovine Viral - isolation & purification</subject><subject>Disaccharides - pharmacology</subject><subject>Disaccharides - therapeutic use</subject><subject>DNA, Viral - genetics</subject><subject>DNA, Viral - metabolism</subject><subject>Drug dosages</subject><subject>Health risks</subject><subject>Health services</subject><subject>Herpesvirus 1, Bovine - drug effects</subject><subject>Herpesvirus 1, Bovine - genetics</subject><subject>Herpesvirus 1, Bovine - isolation & purification</subject><subject>Heterocyclic Compounds - pharmacology</subject><subject>Heterocyclic Compounds - therapeutic use</subject><subject>Infections</subject><subject>Mannheimia haemolytica - drug effects</subject><subject>Mannheimia haemolytica - isolation & purification</subject><subject>Medicine and Health Sciences</subject><subject>Microbial Sensitivity Tests</subject><subject>Nasopharynx - microbiology</subject><subject>Nasopharynx - virology</subject><subject>Nucleic acids</subject><subject>Parainfluenza</subject><subject>Pasteurella multocida - drug effects</subject><subject>Pasteurella multocida - isolation & purification</subject><subject>Pathogens</subject><subject>Polymerase Chain Reaction</subject><subject>Prospective Studies</subject><subject>Respiratory diseases</subject><subject>Respiratory syncytial virus</subject><subject>Respiratory Syncytial Virus, Bovine - drug effects</subject><subject>Respiratory Syncytial Virus, Bovine - genetics</subject><subject>Respiratory Syncytial Virus, Bovine - isolation & purification</subject><subject>Respiratory tract</subject><subject>Risk</subject><subject>Risk Factors</subject><subject>RNA, Viral - genetics</subject><subject>RNA, Viral - metabolism</subject><subject>Treatment Failure</subject><subject>Veterinary medicine</subject><subject>Viruses</subject><issn>1932-6203</issn><issn>1932-6203</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>DOA</sourceid><recordid>eNqNU19r1TAUL6K4Of0GogFBFHavaZPmNi_CGP4ZDCZz-BrS9PQ2M01qkl68H9tvYHp3N1bZg_Qhzcnvz8k5OVn2MsfLnKzyD9du9Faa5eAsLHFBV0VOHmWHOSfFghWYPL73f5A9C-Ea45JUjD3NDkiZU1Jiepj9Ode9jjJqZwNyLaqliuC1NEiNJo4ejtFG-7T9dnp5jKRtUByNjJ13_VZpi8IYFAxR19rouEVtiqNxGMAjD2FIzOj8FkWfZFGQ_WAgoEQbPDRaRW3XSBlttUoObozK9TBlMfdQzkbvEsAnIZCxBxt3ubqNtjAzanQAGWCy6PS6W3gdfqIWoEkJdaBb8OF59qSVJsCL_XqUXX3-dHX6dXF-8eXs9OR8oRgv4gJIyzCuuKL5SrVYVowyknNWkJrQBhelykuGWdtwDqqhleK5BF60VYlVrmpylL2-kR2MC2LfrCAKVqxoSRmnCXF2g2icvBaD1730W-GkFruA82shfdTKgCBQV6tS1WVKijaMVZRTTAgvSFUmf5y0Pu7dxrqHRqUKpabNROcnVndi7TaiqghmJU8C7_YC3v0aIUTR69RZY6QFN-7yrgrOGJu83vwDffh2e9Rapgto27rpEUyi4iQVuOKUFZPt8gFU-hrodeo7tDrFZ4T3M8L0NuB3XMsxBHH2_fL_sRc_5ti397AdSBO74My4G4w5kN4AlXcheGjvipxjMQ3mbTXENJhiP5iJ9up-g-5It5NI_gLc_Tn6</recordid><startdate>20220210</startdate><enddate>20220210</enddate><creator>Sarchet, Jeffrey J</creator><creator>Pollreisz, John P</creator><creator>Bechtol, David T</creator><creator>Blanding, Mitchell R</creator><creator>Saltman, Roger L</creator><creator>Taube, Patrick C</creator><general>Public Library of Science</general><general>Public Library of Science (PLoS)</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>IOV</scope><scope>ISR</scope><scope>3V.</scope><scope>7QG</scope><scope>7QL</scope><scope>7QO</scope><scope>7RV</scope><scope>7SN</scope><scope>7SS</scope><scope>7T5</scope><scope>7TG</scope><scope>7TM</scope><scope>7U9</scope><scope>7X2</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FD</scope><scope>8FE</scope><scope>8FG</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABJCF</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>ARAPS</scope><scope>ATCPS</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BGLVJ</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>D1I</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB.</scope><scope>KB0</scope><scope>KL.</scope><scope>L6V</scope><scope>LK8</scope><scope>M0K</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>M7P</scope><scope>M7S</scope><scope>NAPCQ</scope><scope>P5Z</scope><scope>P62</scope><scope>P64</scope><scope>PATMY</scope><scope>PDBOC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PTHSS</scope><scope>PYCSY</scope><scope>RC3</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0002-6325-090X</orcidid></search><sort><creationdate>20220210</creationdate><title>Limitations of bacterial culture, viral PCR, and tulathromycin susceptibility from upper respiratory tract samples in predicting clinical outcome of tulathromycin control or treatment of bovine respiratory disease in high-risk feeder heifers</title><author>Sarchet, Jeffrey J ; Pollreisz, John P ; Bechtol, David T ; Blanding, Mitchell R ; Saltman, Roger L ; Taube, Patrick C</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c692t-e3f60089c417cf0a8646319623b34d025c15606fd99ecd48c91ae92f850c1cb3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Analysis</topic><topic>Animals</topic><topic>Anti-Bacterial Agents - pharmacology</topic><topic>Anti-Bacterial Agents - therapeutic use</topic><topic>Antimicrobial agents</topic><topic>Bacterial infections</topic><topic>Biology and Life Sciences</topic><topic>Bovine respiratory disease complex</topic><topic>Bovine Respiratory Disease Complex - drug therapy</topic><topic>Bovine Respiratory Disease Complex - microbiology</topic><topic>Bovine Respiratory Disease Complex - pathology</topic><topic>Care and treatment</topic><topic>Cattle</topic><topic>Cattle Diseases - drug therapy</topic><topic>Cattle Diseases - microbiology</topic><topic>Cattle Diseases - pathology</topic><topic>Clinical outcomes</topic><topic>Confidence intervals</topic><topic>Cross-Sectional Studies</topic><topic>Diarrhea</topic><topic>Diarrhea Viruses, Bovine Viral - drug effects</topic><topic>Diarrhea Viruses, Bovine Viral - genetics</topic><topic>Diarrhea Viruses, Bovine Viral - isolation & purification</topic><topic>Disaccharides - pharmacology</topic><topic>Disaccharides - therapeutic use</topic><topic>DNA, Viral - genetics</topic><topic>DNA, Viral - metabolism</topic><topic>Drug dosages</topic><topic>Health risks</topic><topic>Health services</topic><topic>Herpesvirus 1, Bovine - drug effects</topic><topic>Herpesvirus 1, Bovine - genetics</topic><topic>Herpesvirus 1, Bovine - isolation & purification</topic><topic>Heterocyclic Compounds - pharmacology</topic><topic>Heterocyclic Compounds - therapeutic use</topic><topic>Infections</topic><topic>Mannheimia haemolytica - drug effects</topic><topic>Mannheimia haemolytica - isolation & purification</topic><topic>Medicine and Health Sciences</topic><topic>Microbial Sensitivity Tests</topic><topic>Nasopharynx - microbiology</topic><topic>Nasopharynx - virology</topic><topic>Nucleic acids</topic><topic>Parainfluenza</topic><topic>Pasteurella multocida - drug effects</topic><topic>Pasteurella multocida - isolation & purification</topic><topic>Pathogens</topic><topic>Polymerase Chain Reaction</topic><topic>Prospective Studies</topic><topic>Respiratory diseases</topic><topic>Respiratory syncytial virus</topic><topic>Respiratory Syncytial Virus, Bovine - drug effects</topic><topic>Respiratory Syncytial Virus, Bovine - genetics</topic><topic>Respiratory Syncytial Virus, Bovine - isolation & purification</topic><topic>Respiratory tract</topic><topic>Risk</topic><topic>Risk Factors</topic><topic>RNA, Viral - genetics</topic><topic>RNA, Viral - metabolism</topic><topic>Treatment Failure</topic><topic>Veterinary medicine</topic><topic>Viruses</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Sarchet, Jeffrey J</creatorcontrib><creatorcontrib>Pollreisz, John P</creatorcontrib><creatorcontrib>Bechtol, David T</creatorcontrib><creatorcontrib>Blanding, Mitchell R</creatorcontrib><creatorcontrib>Saltman, Roger L</creatorcontrib><creatorcontrib>Taube, Patrick C</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Gale In Context: Opposing Viewpoints</collection><collection>Gale In Context: Science</collection><collection>ProQuest Central (Corporate)</collection><collection>Animal Behavior Abstracts</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Biotechnology Research Abstracts</collection><collection>Nursing & Allied Health Database</collection><collection>Ecology Abstracts</collection><collection>Entomology Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>Meteorological & Geoastrophysical Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Agricultural Science Collection</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Materials Science & Engineering Collection</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>Advanced Technologies & Aerospace Collection</collection><collection>Agricultural & Environmental Science Collection</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Technology Collection</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Materials Science Collection</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Materials Science Database</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Meteorological & Geoastrophysical Abstracts - Academic</collection><collection>ProQuest Engineering Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>Agricultural Science Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Engineering Database</collection><collection>Nursing & Allied Health Premium</collection><collection>Advanced Technologies & Aerospace Database</collection><collection>ProQuest Advanced Technologies & Aerospace Collection</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Environmental Science Database</collection><collection>Materials Science Collection</collection><collection>Access via ProQuest (Open Access)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>Engineering Collection</collection><collection>Environmental Science Collection</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>PloS one</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Sarchet, Jeffrey J</au><au>Pollreisz, John P</au><au>Bechtol, David T</au><au>Blanding, Mitchell R</au><au>Saltman, Roger L</au><au>Taube, Patrick C</au><au>Clegg, Simon</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Limitations of bacterial culture, viral PCR, and tulathromycin susceptibility from upper respiratory tract samples in predicting clinical outcome of tulathromycin control or treatment of bovine respiratory disease in high-risk feeder heifers</atitle><jtitle>PloS one</jtitle><addtitle>PLoS One</addtitle><date>2022-02-10</date><risdate>2022</risdate><volume>17</volume><issue>2</issue><spage>e0247213</spage><epage>e0247213</epage><pages>e0247213-e0247213</pages><issn>1932-6203</issn><eissn>1932-6203</eissn><abstract>A cross-sectional prospective cohort study including 1026 heifers administered tulathromycin due to high risk of clinical signs of bovine respiratory disease (BRD), measured poor association between BRD clinical outcomes and results of bacterial culture and tulathromycin susceptibility from BRD isolates of deep nasopharyngeal swabs (DNS) and adequate association with viral polymerase chain reaction (PCR) results from nasal swabs. Isolation rates from DNS collected on day-0 and at 1st BRD-treatment respectively were: Mannheimia haemolytica (10.9% & 34.1%); Pasteurella multocida (10.4% & 7.4%); Mycoplasma bovis (1.0% & 36.6%); and Histophilus somni (0.7% & 6.3%). Prevalence of BRD viral nucleic acid on nasal swabs collected exclusively at 1st BRD-treatment were: bovine parainfluenza virus type-3 (bPIV-3) 34.1%; bovine viral diarrhea virus (BVDV) 26.3%; bovine herpes virus type-1 (BHV-1) 10.8%; and bovine respiratory syncytial virus (BRSV) 54.1%. Increased relative risk, at 95% confidence intervals, of 1st BRD-treatment failure was associated with positive viral PCR results: BVDV 1.39 (1.17-1.66), bPIV-3 1.26 (1.06-1.51), BHV-1 1.52 (1.25-1.83), and BRSV 1.35 (1.11-1.63) from nasal swabs collected at 1st BRD-treatment and culture of M. haemolytica 1.23 (1.00-1.51) from DNS collected at day-0. However, in this population of high-risk feeder heifers, the predictive values of susceptible and resistant isolates had inadequate association with BRD clinical outcome. These results indicate, that using tulathromycin susceptibility testing of isolates of M. haemolytica or P. multocida from DNS collected on arrival or at 1st BRD-treatment to evaluate tulathromycin clinical efficacy, is unreliable.</abstract><cop>United States</cop><pub>Public Library of Science</pub><pmid>35143504</pmid><doi>10.1371/journal.pone.0247213</doi><tpages>e0247213</tpages><orcidid>https://orcid.org/0000-0002-6325-090X</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1932-6203 |
| ispartof | PloS one, 2022-02, Vol.17 (2), p.e0247213-e0247213 |
| issn | 1932-6203 1932-6203 |
| language | eng |
| recordid | cdi_plos_journals_2627454694 |
| source | Public Library of Science (PLoS) Journals Open Access; MEDLINE; DOAJ Directory of Open Access Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central; Free Full-Text Journals in Chemistry |
| subjects | Analysis Animals Anti-Bacterial Agents - pharmacology Anti-Bacterial Agents - therapeutic use Antimicrobial agents Bacterial infections Biology and Life Sciences Bovine respiratory disease complex Bovine Respiratory Disease Complex - drug therapy Bovine Respiratory Disease Complex - microbiology Bovine Respiratory Disease Complex - pathology Care and treatment Cattle Cattle Diseases - drug therapy Cattle Diseases - microbiology Cattle Diseases - pathology Clinical outcomes Confidence intervals Cross-Sectional Studies Diarrhea Diarrhea Viruses, Bovine Viral - drug effects Diarrhea Viruses, Bovine Viral - genetics Diarrhea Viruses, Bovine Viral - isolation & purification Disaccharides - pharmacology Disaccharides - therapeutic use DNA, Viral - genetics DNA, Viral - metabolism Drug dosages Health risks Health services Herpesvirus 1, Bovine - drug effects Herpesvirus 1, Bovine - genetics Herpesvirus 1, Bovine - isolation & purification Heterocyclic Compounds - pharmacology Heterocyclic Compounds - therapeutic use Infections Mannheimia haemolytica - drug effects Mannheimia haemolytica - isolation & purification Medicine and Health Sciences Microbial Sensitivity Tests Nasopharynx - microbiology Nasopharynx - virology Nucleic acids Parainfluenza Pasteurella multocida - drug effects Pasteurella multocida - isolation & purification Pathogens Polymerase Chain Reaction Prospective Studies Respiratory diseases Respiratory syncytial virus Respiratory Syncytial Virus, Bovine - drug effects Respiratory Syncytial Virus, Bovine - genetics Respiratory Syncytial Virus, Bovine - isolation & purification Respiratory tract Risk Risk Factors RNA, Viral - genetics RNA, Viral - metabolism Treatment Failure Veterinary medicine Viruses |
| title | Limitations of bacterial culture, viral PCR, and tulathromycin susceptibility from upper respiratory tract samples in predicting clinical outcome of tulathromycin control or treatment of bovine respiratory disease in high-risk feeder heifers |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-11-30T23%3A53%3A23IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_plos_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Limitations%20of%20bacterial%20culture,%20viral%20PCR,%20and%20tulathromycin%20susceptibility%20from%20upper%20respiratory%20tract%20samples%20in%20predicting%20clinical%20outcome%20of%20tulathromycin%20control%20or%20treatment%20of%20bovine%20respiratory%20disease%20in%20high-risk%20feeder%20heifers&rft.jtitle=PloS%20one&rft.au=Sarchet,%20Jeffrey%20J&rft.date=2022-02-10&rft.volume=17&rft.issue=2&rft.spage=e0247213&rft.epage=e0247213&rft.pages=e0247213-e0247213&rft.issn=1932-6203&rft.eissn=1932-6203&rft_id=info:doi/10.1371/journal.pone.0247213&rft_dat=%3Cgale_plos_%3EA692894629%3C/gale_plos_%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2627454694&rft_id=info:pmid/35143504&rft_galeid=A692894629&rft_doaj_id=oai_doaj_org_article_3eb875cb53f64d6684940339238599e0&rfr_iscdi=true |